v3.26.1
License and Collaboration Agreements - Overland Therapeutics, Inc. (Details) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
May 12, 2026
Dec. 31, 2025
May 24, 2024
Dec. 14, 2020
Overland Therapeutics (Formerly Known As Allogene Overland)            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Ownership percentage           49.00%
Equity method investments $ 0     $ 0    
Collaboration revenue - related party $ 0 $ 0        
Overland Therapeutics (Formerly Known As Allogene Overland) | Voting Interest            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Ownership percentage 20.00%          
Overland Therapeutics (Formerly Known As Allogene Overland) | Voting Interest | Subsequent Event            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Ownership percentage     3.00%      
Overland Therapeutics (Formerly Known As Allogene Overland) | License            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Revenue, remaining performance obligation, amount $ 4,600,000     $ 4,600,000    
Overland Therapeutics (Formerly Known As Allogene Overland) | License | Maximum            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Revenue, remaining performance obligation, variable consideration amount         $ 115,000,000.0  
Overland Pharmaceuticals Inc. | Overland Therapeutics (Formerly Known As Allogene Overland)            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Ownership percentage           51.00%
Overland Therapeutics (Formerly Known As Allogene Overland)            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Subsidiary, ownership percentage, noncontrolling owner         18.00%  
License agreement, minimum ownership threshold, percent         0.075  
Overland Therapeutics (Formerly Known As Allogene Overland) | Overland Pharmaceuticals Inc.            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Subsidiary, ownership percentage, parent         82.00%  
Overland US | Overland Pharmaceuticals Inc.            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Subsidiary, ownership percentage, parent         100.00%